Header ads

Ivermectin And Sars-CoV-2 - Ivermectin Lowers Viral Load

Ivermectin and Sars-CoV-2

Ivermectin And Sars-CoV-2:

Berlin - Ivermectin is known from the treatment of scabies and rosacea. Australian researchers have published results from an in vitro study of efficacy against SARS-CoV-2. Ivermectin is suitable for the treatment of various parasite infections.

These include intestinal strongyloidiasis, an intestinal infection caused by the roundworm Strongyloides Stercoralis, and microfilaremia in patients with lymphatic filariasis caused by Wuchereria Bancroft.

The drug is also used to treat scabies in humans. Ivermectin binds with high affinity to glutamate-controlled chloride channels in the nerve and muscle cells of itch mites and thus increases the permeability of the membrane to chloride ions.

The cells become hyperpolarized and the parasites paralyze and die. However, ivermectin has also shown antiviral properties in the past.

It has been documented in vitro that the drug can prevent the replication of, for example, HIV, dengue fever, influenza and Zika.

Ivermectin & Sars-CoV-2:


The results of a study on ivermectin and Sars-CoV-2 were published in the specialist magazine "Antiviral Research" last week.

As part of an in vitro study, Australian scientists documented that ivermectin can reduce viral Sars-CoV-2 RNA in so-called Vero cells (Vero-HSLAM) by 93 per cent after 24 hours - a reduction of 99 after 48 hours, 8 per cent are shown.

The data show a 5000-fold reduction in Sars-Cov-2 RNA. The multiplicity of the infection was 0.1 for 2 hours.

On days 0 to 3, replication of the Sars CoV-2 RNA was analyzed. After 24 hours, the viral RNA present in the supernatant of the samples treated with ivermectin was reduced by 93 per cent compared to the vehicle DMSO.

Similarly, a 99.8 per cent reduction in cell-associated viral RNA was observed when treated with ivermectin.

Several well-known drugs for the treatment of COVID-19 are currently being tested, including the Japanese flu drug Avigan (favipiravir) and the drugs Kaletra, Foipan and chloroquine and hydroxychloroquine-containing drugs.

The procured products are distributed through pharmacies from university clinics and pharmacies from treatment centres for the inpatient care of affected patients.


*******

Post a Comment

0 Comments